vs
Journey Medical Corp（DERM）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
Journey Medical Corp的季度营收约是RIVERVIEW BANCORP INC的1.1倍（$16.1M vs $14.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -7.8%，领先17.6%），Journey Medical Corp同比增速更快（27.3% vs 10.4%），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs 11.0%）
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
DERM vs RVSB — 直观对比
营收规模更大
DERM
是对方的1.1倍
$14.0M
营收增速更快
DERM
高出16.9%
10.4%
净利率更高
RVSB
高出17.6%
-7.8%
两年增速更快
RVSB
近两年复合增速
11.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $14.0M |
| 净利润 | $-1.2M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -2.8% | 12.4% |
| 净利率 | -7.8% | 9.8% |
| 营收同比 | 27.3% | 10.4% |
| 净利润同比 | -182.0% | 11.8% |
| 每股收益（稀释后） | $-0.04 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DERMRVSB
| Q4 25 | $16.1M | $14.0M | ||
| Q3 25 | $17.0M | $13.6M | ||
| Q2 25 | $15.0M | $13.3M | ||
| Q1 25 | $13.1M | $12.9M | ||
| Q4 24 | $12.6M | $12.7M | ||
| Q3 24 | $14.6M | $12.8M | ||
| Q2 24 | $14.9M | $12.2M | ||
| Q1 24 | $13.0M | $9.0M |
净利润DERMRVSB
| Q4 25 | $-1.2M | $1.4M | ||
| Q3 25 | $-2.3M | $1.1M | ||
| Q2 25 | $-3.8M | $1.2M | ||
| Q1 25 | $-4.1M | $1.1M | ||
| Q4 24 | $1.5M | $1.2M | ||
| Q3 24 | $-2.4M | $1.6M | ||
| Q2 24 | $-3.4M | $966.0K | ||
| Q1 24 | $-10.4M | $-3.0M |
毛利率DERMRVSB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
营业利润率DERMRVSB
| Q4 25 | -2.8% | 12.4% | ||
| Q3 25 | -9.0% | 10.2% | ||
| Q2 25 | -19.2% | 11.7% | ||
| Q1 25 | -25.3% | 11.3% | ||
| Q4 24 | 17.7% | 12.4% | ||
| Q3 24 | -19.8% | 15.5% | ||
| Q2 24 | -19.7% | 10.0% | ||
| Q1 24 | -77.4% | -47.5% |
净利率DERMRVSB
| Q4 25 | -7.8% | 9.8% | ||
| Q3 25 | -13.6% | 8.1% | ||
| Q2 25 | -25.3% | 9.2% | ||
| Q1 25 | -31.0% | 8.9% | ||
| Q4 24 | 12.1% | 9.7% | ||
| Q3 24 | -16.3% | 12.2% | ||
| Q2 24 | -22.6% | 7.9% | ||
| Q1 24 | -80.1% | -34.7% |
每股收益（稀释后）DERMRVSB
| Q4 25 | $-0.04 | $0.07 | ||
| Q3 25 | $-0.09 | $0.05 | ||
| Q2 25 | $-0.16 | $0.06 | ||
| Q1 25 | $-0.18 | $0.05 | ||
| Q4 24 | $0.10 | $0.06 | ||
| Q3 24 | $-0.12 | $0.07 | ||
| Q2 24 | $-0.17 | $0.05 | ||
| Q1 24 | $-0.53 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | $28.6M |
| 总债务越低越好 | $25.3M | — |
| 股东权益账面价值 | $31.9M | $164.2M |
| 总资产 | $94.6M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资DERMRVSB
| Q4 25 | $24.1M | $28.6M | ||
| Q3 25 | $24.9M | $32.8M | ||
| Q2 25 | $20.3M | $34.2M | ||
| Q1 25 | $21.1M | $29.4M | ||
| Q4 24 | $20.3M | $25.3M | ||
| Q3 24 | $22.5M | $31.0M | ||
| Q2 24 | $23.9M | $27.8M | ||
| Q1 24 | $24.1M | $23.6M |
总债务DERMRVSB
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
股东权益DERMRVSB
| Q4 25 | $31.9M | $164.2M | ||
| Q3 25 | $25.9M | $163.5M | ||
| Q2 25 | $19.2M | $162.0M | ||
| Q1 25 | $21.5M | $160.0M | ||
| Q4 24 | $20.1M | $158.3M | ||
| Q3 24 | $10.9M | $160.8M | ||
| Q2 24 | $11.3M | $155.9M | ||
| Q1 24 | $13.0M | $155.6M |
总资产DERMRVSB
| Q4 25 | $94.6M | $1.5B | ||
| Q3 25 | $85.2M | $1.5B | ||
| Q2 25 | $81.2M | $1.5B | ||
| Q1 25 | $85.0M | $1.5B | ||
| Q4 24 | $80.2M | $1.5B | ||
| Q3 24 | $64.0M | $1.5B | ||
| Q2 24 | $65.2M | $1.5B | ||
| Q1 24 | $66.6M | $1.5B |
负债/权益比DERMRVSB
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.3M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | — | $-736.0K |
| 自由现金流率自由现金流/营收 | — | -5.2% |
| 资本支出强度资本支出/营收 | — | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | — | $20.4M |
8季度趋势，按日历期对齐
经营现金流DERMRVSB
| Q4 25 | $-6.3M | $-506.0K | ||
| Q3 25 | $-2.4M | $16.8M | ||
| Q2 25 | $-942.0K | $-697.0K | ||
| Q1 25 | $-2.8M | $8.3M | ||
| Q4 24 | $2.2M | $2.2M | ||
| Q3 24 | $-1.2M | $764.0K | ||
| Q2 24 | $-5.2M | $5.4M | ||
| Q1 24 | $-5.0M | $12.8M |
自由现金流DERMRVSB
| Q4 25 | — | $-736.0K | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | — | $-773.0K | ||
| Q1 25 | — | $5.6M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $5.3M | ||
| Q1 24 | — | $7.1M |
自由现金流率DERMRVSB
| Q4 25 | — | -5.2% | ||
| Q3 25 | — | 120.1% | ||
| Q2 25 | — | -5.8% | ||
| Q1 25 | — | 43.1% | ||
| Q4 24 | — | 15.0% | ||
| Q3 24 | — | -11.3% | ||
| Q2 24 | — | 43.7% | ||
| Q1 24 | — | 79.0% |
资本支出强度DERMRVSB
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 21.0% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 17.3% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 62.0% |
现金转化率DERMRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | 1.46× | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
RVSB
暂无分部数据
